S'abonner

Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale - 18/04/17

Doi : 10.1016/j.ahj.2016.12.012 
Gordon R. Reeves a, , 1 , David J. Whellan a, 1, Pamela Duncan b, Christopher M. O'Connor c, Amy M. Pastva d, Joel D. Eggebeen e, Leigh Ann Hewston f, Timothy M. Morgan b, Shelby D. Reed d, W. Jack Rejeski g, Robert J. Mentz d, Paul B. Rosenberg d, Dalane W. Kitzman b

on behalf of the REHAB-HF Trial Investigators

a Sidney Kimmel Medical College, Philadelphia, PA 
b Wake Forest School of Medicine, Winston-Salem, NC 
c Inova Heart and Vascular Institute, Falls Church, VA 
d Duke University School of Medicine, Durham, NC 
e Emory Univeristy, Atlanta, GA 
f Thomas Jefferson University School of Health Professions, Philadelphia, PA 
g Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC 

Reprint requests: Gordon R. Reeves, MD, MPT, Department of Medicine, Sidney Kimmel School of Medicine at Thomas Jefferson University, 925 Chestnut Street, Mezzanine Level, Philadelphia, PA, 19107.Department of MedicineSidney Kimmel School of Medicine at Thomas Jefferson University925 Chestnut Street, Mezzanine LevelPhiladelphiaPA19107

Abstract

Background

Acute decompensated heart failure (ADHF) is a leading cause of hospitalization in older persons in the United States. Reduced physical function and frailty are major determinants of adverse outcomes in older patients with hospitalized ADHF. However, these are not addressed by current heart failure (HF) management strategies and there has been little study of exercise training in older, frail HF patients with recent ADHF.

Hypothesis

Targeting physical frailty with a multi-domain structured physical rehabilitation intervention will improve physical function and reduce adverse outcomes among older patients experiencing a HF hospitalization.

Study design

REHAB-HF is a multi-center clinical trial in which 360 patients ≥60 years hospitalized with ADHF will be randomized either to a novel 12-week multi-domain physical rehabilitation intervention or to attention control. The goal of the intervention is to improve balance, mobility, strength and endurance utilizing reproducible, targeted exercises administered by a multi-disciplinary team with specific milestones for progression. The primary study aim is to assess the efficacy of the REHAB-HF intervention on physical function measured by total Short Physical Performance Battery score. The secondary outcome is 6-month all-cause rehospitalization. Additional outcome measures include quality of life and costs.

Conclusions

REHAB-HF is the first randomized trial of a physical function intervention in older patients with hospitalized ADHF designed to determine if addressing deficits in balance, mobility, strength and endurance improves physical function and reduces rehospitalizations. It will address key evidence gaps concerning the role of physical rehabilitation in the care of older patients, those with ADHF, frailty, and multiple comorbidities.

Le texte complet de cet article est disponible en PDF.

Abbreviations : ADHF, HF, CMS, EQ-5D-5 L, SPPB, REHAB-HF, QOL, RPE, EF, HFrEF, HFpEF


Plan


 Michael P. Hudson, MD served as guest editor for this article.
 Clinicaltrials.gov number: NCT02196038
 Financial Support: This study is supported by the following research grants: NIH Grants R01AG045551 and R01AG18915; The Claude D. Pepper Older Americans Independence Center of Wake Forest School of Medicine Winston-Salem, NC, NIH Grant P30AG021332; the Kermit Glenn Phillips II Endowed Chair in Cardiology; Dean's Faculty Achievement Award, Jefferson College of Health Professions, Philadelphia, PA; and the Oristano Family Research Fund. RJM receives additional research support from the National Institutes of Health (U10HL110312). AMP receives additional research support from The Claude D. Pepper Older Americans Independence Center of Duke University School of Medicine, Durham, NC, NIH Grant P30AG028716.


© 2017  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 185

P. 130-139 - mars 2017 Retour au numéro
Article précédent Article précédent
  • A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial
  • Heesun Lee, Bon-Kwon Koo, Kyung Woo Park, Eun-Seok Shin, Sang Wook Lim, Seung-Woon Rha, Jang-Whan Bae, Dong Woon Jeon, Seok-Kyu Oh, Seung-Ho Hur, Bum-Su Kim, Jung-Hee Lee, Tae-Ho Park, Nam Ho Lee, Hyo-Soo Kim, HOST-EXAM investigators
| Article suivant Article suivant
  • Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial
  • Mark D. Huffman, Padinhare Purayil Mohanan, Raji Devarajan, Abigail S. Baldridge, Dimple Kondal, Lihui Zhao, Mumtaj Ali, Donald M. Lloyd-Jones, Dorairaj Prabhakaran

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.